Syracuse, NY, United States
Syracuse, NY, United States

Time filter

Source Type

News Article | December 12, 2016
Site: globenewswire.com

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel immuno-oncology agents, announced today that it has appointed Linda Kozick to its board of directors. Linda brings more than 25 years of experience in the biopharmaceutical industry, including 15 years of strategic commercial leadership in oncology, specializing in immuno-oncology. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a90c227f-b0d7-49cf-993c-8d76d11a5177. "We are delighted to welcome Linda to the FLX Bio board as the company advances its growing immuno-oncology and targeted oncology pipeline. Linda’s leadership in developing commercial strategies for key immuno-oncology therapies makes her an ideal candidate to help FLX Bio navigate clinical and commercial opportunities with our strong pipeline of product candidates,” said Dr. Brian Wong, CEO of FLX Bio. “FLX Bio has a strong discovery platform and has built a highly differentiated pipeline of immuno-oncology and targeted oncology compounds,” said Ms. Kozick. “I am delighted to join the FLX Bio Board of Directors to work alongside FLX Bio’s outstanding executive team, Board of Directors and Scientific Advisory Board members to realize the company’s goal of bringing best-in-class, next generation oncology therapies to patients." Ms. Kozick recently retired from Bristol-Myers Squibb (BMS) after 26 years. Most recently, she served as Vice President and Head of Immuno-Oncology/Oncology Product & Portfolio Strategy, and Opdivo and Yervoy Life Cycle Management. Prior to that, Ms. Kozick held several key positions including Vice President, Commercial Lead for Opdivo and Immuno-Oncology Platform Strategy, and was instrumental in establishing BMS’s International Immuno-Oncology Network (II-ON). Ms. Kozick received her Bachelor of Science and Master of Science degrees from Upstate Medical Center, and her Master’s in Business Administration from Chapman University. Founded in 2015 following the acquisition of its predecessor company, Flexus Biosciences, Inc., by Bristol-Myers Squibb, FLX Bio, Inc. is a privately-held biopharmaceutical company focused on the discovery, development and commercialization of novel immuno-oncology agents. The company leverages its unique insights in cancer biology and the immune system to discover and develop novel oral medicines that activate immune responses to eliminate cancer cells. Located in South San Francisco, Calif., and funded by leading investors, including Kleiner Perkins Caufield & Byers (KPCB), The Column Group (TCG) and Celgene, FLX Bio has assembled a management and R&D leadership team with a proven track record of success and an advisory group and team of scientists with substantial knowledge and expertise in drug discovery and translational areas essential to execute on this approach. For more information, please visit www.flxbio.com.


News Article | December 12, 2016
Site: globenewswire.com

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel immuno-oncology agents, announced today that it has appointed Linda Kozick to its board of directors. Linda brings more than 25 years of experience in the biopharmaceutical industry, including 15 years of strategic commercial leadership in oncology, specializing in immuno-oncology. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a90c227f-b0d7-49cf-993c-8d76d11a5177. "We are delighted to welcome Linda to the FLX Bio board as the company advances its growing immuno-oncology and targeted oncology pipeline. Linda’s leadership in developing commercial strategies for key immuno-oncology therapies makes her an ideal candidate to help FLX Bio navigate clinical and commercial opportunities with our strong pipeline of product candidates,” said Dr. Brian Wong, CEO of FLX Bio. “FLX Bio has a strong discovery platform and has built a highly differentiated pipeline of immuno-oncology and targeted oncology compounds,” said Ms. Kozick. “I am delighted to join the FLX Bio Board of Directors to work alongside FLX Bio’s outstanding executive team, Board of Directors and Scientific Advisory Board members to realize the company’s goal of bringing best-in-class, next generation oncology therapies to patients." Ms. Kozick recently retired from Bristol-Myers Squibb (BMS) after 26 years. Most recently, she served as Vice President and Head of Immuno-Oncology/Oncology Product & Portfolio Strategy, and Opdivo and Yervoy Life Cycle Management. Prior to that, Ms. Kozick held several key positions including Vice President, Commercial Lead for Opdivo and Immuno-Oncology Platform Strategy, and was instrumental in establishing BMS’s International Immuno-Oncology Network (II-ON). Ms. Kozick received her Bachelor of Science and Master of Science degrees from Upstate Medical Center, and her Master’s in Business Administration from Chapman University. Founded in 2015 following the acquisition of its predecessor company, Flexus Biosciences, Inc., by Bristol-Myers Squibb, FLX Bio, Inc. is a privately-held biopharmaceutical company focused on the discovery, development and commercialization of novel immuno-oncology agents. The company leverages its unique insights in cancer biology and the immune system to discover and develop novel oral medicines that activate immune responses to eliminate cancer cells. Located in South San Francisco, Calif., and funded by leading investors, including Kleiner Perkins Caufield & Byers (KPCB), The Column Group (TCG) and Celgene, FLX Bio has assembled a management and R&D leadership team with a proven track record of success and an advisory group and team of scientists with substantial knowledge and expertise in drug discovery and translational areas essential to execute on this approach. For more information, please visit www.flxbio.com.


News Article | December 12, 2016
Site: globenewswire.com

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel immuno-oncology agents, announced today that it has appointed Linda Kozick to its board of directors. Linda brings more than 25 years of experience in the biopharmaceutical industry, including 15 years of strategic commercial leadership in oncology, specializing in immuno-oncology. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a90c227f-b0d7-49cf-993c-8d76d11a5177. "We are delighted to welcome Linda to the FLX Bio board as the company advances its growing immuno-oncology and targeted oncology pipeline. Linda’s leadership in developing commercial strategies for key immuno-oncology therapies makes her an ideal candidate to help FLX Bio navigate clinical and commercial opportunities with our strong pipeline of product candidates,” said Dr. Brian Wong, CEO of FLX Bio. “FLX Bio has a strong discovery platform and has built a highly differentiated pipeline of immuno-oncology and targeted oncology compounds,” said Ms. Kozick. “I am delighted to join the FLX Bio Board of Directors to work alongside FLX Bio’s outstanding executive team, Board of Directors and Scientific Advisory Board members to realize the company’s goal of bringing best-in-class, next generation oncology therapies to patients." Ms. Kozick recently retired from Bristol-Myers Squibb (BMS) after 26 years. Most recently, she served as Vice President and Head of Immuno-Oncology/Oncology Product & Portfolio Strategy, and Opdivo and Yervoy Life Cycle Management. Prior to that, Ms. Kozick held several key positions including Vice President, Commercial Lead for Opdivo and Immuno-Oncology Platform Strategy, and was instrumental in establishing BMS’s International Immuno-Oncology Network (II-ON). Ms. Kozick received her Bachelor of Science and Master of Science degrees from Upstate Medical Center, and her Master’s in Business Administration from Chapman University. Founded in 2015 following the acquisition of its predecessor company, Flexus Biosciences, Inc., by Bristol-Myers Squibb, FLX Bio, Inc. is a privately-held biopharmaceutical company focused on the discovery, development and commercialization of novel immuno-oncology agents. The company leverages its unique insights in cancer biology and the immune system to discover and develop novel oral medicines that activate immune responses to eliminate cancer cells. Located in South San Francisco, Calif., and funded by leading investors, including Kleiner Perkins Caufield & Byers (KPCB), The Column Group (TCG) and Celgene, FLX Bio has assembled a management and R&D leadership team with a proven track record of success and an advisory group and team of scientists with substantial knowledge and expertise in drug discovery and translational areas essential to execute on this approach. For more information, please visit www.flxbio.com.


News Article | December 12, 2016
Site: globenewswire.com

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel immuno-oncology agents, announced today that it has appointed Linda Kozick to its board of directors. Linda brings more than 25 years of experience in the biopharmaceutical industry, including 15 years of strategic commercial leadership in oncology, specializing in immuno-oncology. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a90c227f-b0d7-49cf-993c-8d76d11a5177. "We are delighted to welcome Linda to the FLX Bio board as the company advances its growing immuno-oncology and targeted oncology pipeline. Linda’s leadership in developing commercial strategies for key immuno-oncology therapies makes her an ideal candidate to help FLX Bio navigate clinical and commercial opportunities with our strong pipeline of product candidates,” said Dr. Brian Wong, CEO of FLX Bio. “FLX Bio has a strong discovery platform and has built a highly differentiated pipeline of immuno-oncology and targeted oncology compounds,” said Ms. Kozick. “I am delighted to join the FLX Bio Board of Directors to work alongside FLX Bio’s outstanding executive team, Board of Directors and Scientific Advisory Board members to realize the company’s goal of bringing best-in-class, next generation oncology therapies to patients." Ms. Kozick recently retired from Bristol-Myers Squibb (BMS) after 26 years. Most recently, she served as Vice President and Head of Immuno-Oncology/Oncology Product & Portfolio Strategy, and Opdivo and Yervoy Life Cycle Management. Prior to that, Ms. Kozick held several key positions including Vice President, Commercial Lead for Opdivo and Immuno-Oncology Platform Strategy, and was instrumental in establishing BMS’s International Immuno-Oncology Network (II-ON). Ms. Kozick received her Bachelor of Science and Master of Science degrees from Upstate Medical Center, and her Master’s in Business Administration from Chapman University. Founded in 2015 following the acquisition of its predecessor company, Flexus Biosciences, Inc., by Bristol-Myers Squibb, FLX Bio, Inc. is a privately-held biopharmaceutical company focused on the discovery, development and commercialization of novel immuno-oncology agents. The company leverages its unique insights in cancer biology and the immune system to discover and develop novel oral medicines that activate immune responses to eliminate cancer cells. Located in South San Francisco, Calif., and funded by leading investors, including Kleiner Perkins Caufield & Byers (KPCB), The Column Group (TCG) and Celgene, FLX Bio has assembled a management and R&D leadership team with a proven track record of success and an advisory group and team of scientists with substantial knowledge and expertise in drug discovery and translational areas essential to execute on this approach. For more information, please visit www.flxbio.com.


News Article | December 12, 2016
Site: globenewswire.com

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel immuno-oncology agents, announced today that it has appointed Linda Kozick to its board of directors. Linda brings more than 25 years of experience in the biopharmaceutical industry, including 15 years of strategic commercial leadership in oncology, specializing in immuno-oncology. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a90c227f-b0d7-49cf-993c-8d76d11a5177. "We are delighted to welcome Linda to the FLX Bio board as the company advances its growing immuno-oncology and targeted oncology pipeline. Linda’s leadership in developing commercial strategies for key immuno-oncology therapies makes her an ideal candidate to help FLX Bio navigate clinical and commercial opportunities with our strong pipeline of product candidates,” said Dr. Brian Wong, CEO of FLX Bio. “FLX Bio has a strong discovery platform and has built a highly differentiated pipeline of immuno-oncology and targeted oncology compounds,” said Ms. Kozick. “I am delighted to join the FLX Bio Board of Directors to work alongside FLX Bio’s outstanding executive team, Board of Directors and Scientific Advisory Board members to realize the company’s goal of bringing best-in-class, next generation oncology therapies to patients." Ms. Kozick recently retired from Bristol-Myers Squibb (BMS) after 26 years. Most recently, she served as Vice President and Head of Immuno-Oncology/Oncology Product & Portfolio Strategy, and Opdivo and Yervoy Life Cycle Management. Prior to that, Ms. Kozick held several key positions including Vice President, Commercial Lead for Opdivo and Immuno-Oncology Platform Strategy, and was instrumental in establishing BMS’s International Immuno-Oncology Network (II-ON). Ms. Kozick received her Bachelor of Science and Master of Science degrees from Upstate Medical Center, and her Master’s in Business Administration from Chapman University. Founded in 2015 following the acquisition of its predecessor company, Flexus Biosciences, Inc., by Bristol-Myers Squibb, FLX Bio, Inc. is a privately-held biopharmaceutical company focused on the discovery, development and commercialization of novel immuno-oncology agents. The company leverages its unique insights in cancer biology and the immune system to discover and develop novel oral medicines that activate immune responses to eliminate cancer cells. Located in South San Francisco, Calif., and funded by leading investors, including Kleiner Perkins Caufield & Byers (KPCB), The Column Group (TCG) and Celgene, FLX Bio has assembled a management and R&D leadership team with a proven track record of success and an advisory group and team of scientists with substantial knowledge and expertise in drug discovery and translational areas essential to execute on this approach. For more information, please visit www.flxbio.com.


Fiese B.H.,University of Illinois at Urbana - Champaign | Winter M.A.,University of Rochester | Botti J.C.,Upstate Medical Center
Child Development | Year: 2011

Family mealtimes have the potential to promote healthy child development. This observational study of 200 family mealtimes examined the relation between child health in a group of children (ages 5 to 12) with persistent asthma and 3 dimensions of mealtime interaction: Action, Behavior Control, and Communication. Percent time spent in Action and Positive Communication varied by asthma severity, child quality of life, and sociodemographic variables. Positive communication during mealtimes predicted child quality of life. Significant interactions between demographic variables and behavior control suggested that higher levels of behavior control affected child quality of life in the context of lower maternal education. Guidance is offered for practitioners and policy makers toward promoting healthy family mealtimes as a public health priority. © 2011 The Authors. Child Development © 2011 Society for Research in Child Development, Inc.


Asselin B.L.,University of Rochester | Devidas M.,University of Florida | Wang C.,University of Florida | Pullen J.,University of Mississippi Medical Center | And 4 more authors.
Blood | Year: 2011

The Pediatric Oncology Group (POG) phase 3 trial 9404 was designed to determine the effectiveness of high-dose methotrexate (HDM) when added to multiagent chemotherapy based on the Dana-Farber backbone. Children with T-cell acute lymphoblastic leukemia (T-ALL) or advanced lymphoblastic lymphoma (T-NHL) were randomized at diagnosis to receive/not receive HDM (5 g/m2 as a 24-hour infusion) at weeks 4, 7, 10, and 13. Between 1996 and 2000, 436 patients were enrolled in the methotrexate randomization. Five-year and 10-year event-free survival (EFS) was 80.2% ± 2.8% and 78.1% ± 4.3% for HDM (n = 219) versus 73.6% ± 3.1% and 72.6% ± 5.0% for no HDM (n = 217; P = .17). For T-ALL, 5-year and 10-year EFS was significantly better with HDM (n = 148, 5 years: 79.5% ± 3.4%, 10 years: 77.3% ± 5.3%) versus no HDM (n = 151, 5 years: 67.5% ± 3.9%, 10 years: 66.0% ± 6.6%; P = .047). The difference in EFS between HDM and no HDM was not significant for T-NHL patients (n = 71, 5 years: 81.7% ± 4.9%, 10 years: 79.9% ± 7.5% vs n = 66, 5 years: 87.8% ± 4.2%, 10 years: 87.8% ± 6.4%; P = .38). The frequency of mucositis was significantly higher in patients treated with HDM (P = .003). The results support adding HDM to the treatment of children with T-ALL, but not with NHL, despite the increased risk of mucositis. © 2011 by The American Society of Hematology.


McDermott S.,University of South Carolina | Turk M.A.,Upstate Medical Center
Disability and Health Journal | Year: 2011

The concept of disability has medical, functional, and social components. We review the frameworks for the definition of disability and endorse a multidimensional approach that is parsimonious and has utility for epidemiology. We need to be able to count people with disabilities to quantify service and support needs, to study the life course of people with specific disabilities, and to accurately target prevention strategies. In addition, it is important to have some precise measures of disability so comparisons can be made between impairments, to identify disparities and differences, and to measure changes over time. We need to ensure that there is no confusion about cause and effect (attributing associated conditions as outcomes of disability when they are in fact the cause of the functional limitation) and that comparisons to people without disabilities are fair. If people who experience disability due to a condition such as obesity are included in the case definition of disability, then we cannot say people with disability are more likely to be obese. The credibility of disability epidemiology and the disability field is at stake. © 2011 Elsevier Inc. All rights reserved.


Bratslavsky G.,Upstate Medical Center | Cheng J.-S.,Massachusetts General Hospital
Urology | Year: 2015

Objective To describe a case of robotic-assisted radical nephrectomy (RARN) with level III retrohepatic vena caval tumor thrombectomy (11 cm) and extended retroperitoneal lymph node dissection (RPLND) for renal cell carcinoma (RCC). Materials and Methods A 52-year-old woman with a large right renal mass, 11-cm (level III) inferior vena cava (IVC) thrombus, with a negative metastatic workup presented to our clinic and was consented to undergo RARN. Intraoperative ultrasound confirmed the presence of tumor thrombus. After the division of the renal artery, control of the vena cava above and below the tumor thrombus as well as contralateral renal vein was obtained. A cavotomy was performed, the thrombus was removed, and the cavotomy was repaired. Additionally, an extended RPLND was performed with robotic assistance. Results Total operative time was 6 hours and 6 minutes. Estimated blood loss was 1200 cc. The final pathology demonstrated an 8.5-cm, Fuhrman grade 3, clear cell RCC with sarcomatoid features and negative surgical margins. All 44 lymph nodes removed (hilar, paracaval, precaval, retrocaval, interaortocaval, and preaortic) were negative. Final staging was pT3b, N0, M0. The patient was discharged to home 36 hours postoperatively and experienced no perioperative or postoperative complications. Conclusion RARN with retrohepatic (level III) vena caval tumor thrombectomy and extended RPLND is technically feasible and has potential benefits. Robotic assistance may allow for improved intracorporal repair of the IVC and shortened recovery time, while maintaining oncologic principles. © 2015 Elsevier Inc.


News Article | December 9, 2016
Site: www.prweb.com

Mediaplanet today announces distribution of the latest edition of “Transplants,” a cross-platform campaign that raises awareness for organ transplantation while encouraging readers to sign up as an organ donor for the 123,000 people in the United States who are currently waiting for a lifesaving organ transplant. An organ donor can save up to 8 saves through organ donation and enhance many others through tissue donation, however thousands die every year waiting for a donor organ that never comes. Throughout the campaign we look at the impact an organ and/or bone marrow donation can make while highlighting the best resources and services available that are working to make sure we continue to see progress in the transplant field. Actress & Organ Donation Advocate, Katherine Heigl, speaks out about her family’s tragic loss of her brother and the compassionate act that saved four lives in the print and digital campaign. In an exclusive interview with Mediaplanet, Katherine and her mother, Nancy Heigl, share their story in hopes to continue to spread awareness on organ donation. “We knew that a young man got his heart and two people got their sight back,” she says. “Who received them didn’t matter other than that they saved other lives.” The family’s act gave 4 different people another chance and while the decision was tough they knew it was the right one. “Even in the midst of unimaginable pain and sorrow, I knew that we needed to have as much compassion for others as we had for ourselves”, Nancy Heigl adds. The print component of “Transplants” is distributed within the December 9th issue of USA Today in New York, LA, Boston, Chicago, Washington D.C./Baltimore, St. Louis, and Philadelphia with a circulation of approximately 250,000 copies and an estimated readership of 750,000 readers. The digital component is distributed nationally, through a vast social media strategy, and across a network of top news sites and partner outlets. To explore the digital version of the campaign, click here. This edition of “Transplants” was made possible with the support of the American Society of Transplantation, UNOS, Donate Life, UPMC, UW Health, Katherine & Nancy Heigl, DKMS, University of Utah Health Care, SUNY Upstate Medical Center, American College of Cardiology, Chris Klug Foundation, University Colorado Health, Syncardia, Transplant Solutions and many more. About Mediaplanet: Mediaplanet is the leading independent publisher of content-marketing campaigns covering a variety of topics and industries. We turn consumer interest into action by providing readers with motivational editorial, pairing it with relevant advertisers, and distributing it within top newspapers and online platforms around the world.

Loading Upstate Medical Center collaborators
Loading Upstate Medical Center collaborators